ID   HeLa-APL
AC   CVCL_9493
SY   HeLa-R
DR   Wikidata; Q54882709
RX   PubMed=15365569;
RX   PubMed=17338558;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:90205; Plitidepsin (Dehydrodidemnin B; Aplidin).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 16
//
RX   PubMed=15365569; DOI=10.1038/sj.bjc.6602166;
RA   Losada A., Lopez-Oliva J.M., Sanchez-Puelles J.M.,
RA   Garcia-Fernandez L.F.;
RT   "Establishment and characterisation of a human carcinoma cell line
RT   with acquired resistance to aplidin.";
RL   Br. J. Cancer 91:1405-1413(2004).
//
RX   PubMed=17338558; DOI=10.1021/pr060430+;
RA   Gonzalez-Santiago L., Alfonso P., Suarez Y., Nunez A.,
RA   Garcia-Fernandez L.F., Alvarez E., Munoz A., Casal J.I.;
RT   "Proteomic analysis of the resistance to aplidin in human cancer
RT   cells.";
RL   J. Proteome Res. 6:1286-1294(2007).
//